P3 Health Partners (PIII) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 10, 2026

Source: earnings call transcript

Executive summary

P3 Health Partners Q2 FY26 — Strong Performance and Raised Outlook Driven by Operational Execution and Payer Settlements

P3 Health Partners reported a strong second quarter, driven by robust operational execution and significant one-time payer settlements. The company raised its full-year adjusted EBITDA outlook, reflecting confidence in its underlying business and improved payer economics. Management highlighted sustained progress in medical cost management, quality performance, and disciplined growth, positioning the company for more predictable earnings.

Highlights

Delivered $54 million of adjusted EBITDA in Q2 FY26, bringing H1 FY26 total to $80 million.
Raised full-year 2026 adjusted EBITDA outlook to a range of $80 million to $110 million, with a midpoint of $95 million.
MA medical cost trend for H1 FY26 was 1.8% lower than full-year 2025 baseline, a significant differentiator.
Quality performance is tracking ahead of internal glide path towards 4 stars on HEDIS and medication adherence measures.
Per member funding for at-risk population improved approximately 15% year-over-year despite lower membership.

Concerns

Total at-risk membership declined to approximately 105,000 at the end of Q2 FY26, down from 116,000 in Q2 FY25.
Q2 FY26 adjusted EBITDA included $45 million from favorable payer settlements and prior year development, with underlying EBITDA at $9 million.

Guidance & targets

Category	Target	Timeline	Confidence
Full-year 2026 Adjusted EBITDA	$80 million to $110 million high materiality	FY26	High

Deals & partnerships

Payer partners in Nebraska Engagement for geographic expansion 2026-2028

Executing on expected trajectory. Company will perform services in 2027, with full risk arrangement beginning in 2028. This sequencing reduces downside exposure and positions for disciplined full-risk entry.

Risks & headwinds

Membership decline Year-over-year

At-risk membership at 105,000 in Q2 FY26, down from 116,000 in Q2 FY25

Mitigation:Reflects deliberate portfolio actions to exit arrangements not meeting economic thresholds; current membership base is more concentrated in relationships where the model performs best.

Seasonal build in medical expense trend Second half of the year

Not quantified, but noted as 'typical'

Mitigation:Actively managing through care management, utilization management, and payment integrity programs.

What to watch in Q3 FY26

Underlying Adjusted EBITDA

Next quarter (Q3 FY26)

Current $18 million (H1 FY26)

Target Continued positive underlying EBITDA, contributing to FY26 midpoint of $95 million

Why it matters

Management stated the core business is now generating positive adjusted EBITDA, excluding one-time settlements. Continued growth in underlying EBITDA is crucial for demonstrating sustainable profitability.

Excluding those items, underlying first half adjusted EBITDA was approximately $18 million. For us, this is an important milestone. It shows the improvement in our economics is not solely dependent on contractual settlements for prior period development, the core business itself is now generating positive adjusted EBITDA.

Find out whether PIII delivers this. Inve re-checks your case every morning.

Q&A highlights

Can you clarify the nature and size of the payer settlement, its impact on revenue/expense, and provide insight into the seasonality of earnings for the back half of the year?

The Q2 payer settlement was $41 million, impacting only medical claims expense, not revenue. The underlying H1 EBITDA was $18 million, and the guidance midpoint implies an additional $15 million in underlying EBITDA for H2, factoring in typical seasonal medical expense pressure offset by in-year programmatic efforts. The MA medical cost trend is down 1.8% compared to FY25.

“specifically, the payer settlement amount was $41 million, and that did not affect revenue that only affected medical claims expense.”

asked by Ryan Langston · answered by Leif Pedersen

2 min read 6 chapters

Detailed narrative

Operational Execution and Technology Adoption

P3 Health Partners emphasized strong operational execution, expanding point-of-care tools to over 65,000 lives, ahead of schedule. These AI-enhanced tools help clinicians address nearly 90% of care gaps at the point of care and improve coding accuracy. The company is focused on in-office training to increase tool adoption, currently used in approximately half of eligible visits, and aims to close this gap.

Payer Partnerships and Contract Structure

The company highlighted the success of its redesigned payer partnerships and contract structures, initiated 18 months prior. This work focused on enhancing risk profiles, funding mechanisms, and cost accountability. Q2 performance included $45 million in one-time nonrecurring settlements from multiple payer contracts, reflecting improved alignment and trust with partners.

Disciplined Growth and Geographic Expansion

P3 is pursuing disciplined growth, with its engagement in Nebraska progressing positively. The company plans to remain in a service-based relationship in Nebraska through 2027 before transitioning to a full-risk arrangement in 2028. This deliberate approach to geographic expansion aims to validate performance and reduce downside exposure before taking on full risk.

Clinical Performance and Medical Cost Management

Clinical programs, point-of-care technology, and utilization management are driving significant financial results. The MA medical cost trend for the first half of 2026 was 1.8% lower than the full-year 2025 baseline, a sustained differentiator. The care management team and senior wellness centers saw 87% of patients in Q2, including 99.5% of high-risk members, contributing to better outcomes and cost control.

Quality Outcomes and Provider Engagement

Quality performance is tracking ahead of the internal glide path for 4 stars on HEDIS and medication adherence measures. The company improved alternative submissions threefold compared to the prior year, impacting 20% more members. The P3 Restore program, a clinician coaching initiative, expanded across four markets, supporting provider stability, engagement, and practice satisfaction.

Financial Stability and Liquidity

P3 ended the quarter with $21 million in cash and equivalents, maintaining capital discipline and focusing on financial stability. The underlying business is now generating positive adjusted EBITDA, with $18 million in the first half of 2026, excluding one-time settlements, marking an important milestone for the company's economic improvement.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.